StocksMedium•11 November 2026•
1 min read
Novartis Reaches Development Milestone for Ianalumab Ahead of FDA Decision
Key Facts
1Novartis has achieved a significant development milestone for its drug candidate ianalumab as it approaches a regulatory decision from the FDA.
Novartis has achieved a significant development milestone for its drug candidate ianalumab as it approaches a regulatory decision from the U.S. Food and Drug Administration (FDA). Benzinga reported that this progress marks a key step in the clinical pathway for the treatment ahead of upcoming regulatory reviews.
NVS closed at $163.26 on November 10, 2026. The stock reached a high of $164.18 and a low of $162.36 during that session, as the company continues to advance its biological drug pipeline through the regulatory process.